AXOGEN INC (AXGN) Stock Fundamental Analysis
NASDAQ:AXGN - Nasdaq - US05463X1063 - Common Stock - Currency: USD
Overall AXGN gets a fundamental rating of 4 out of 10. We evaluated AXGN against 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of AXGN is average, but there are quite some concerns on its profitability. AXGN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AXGN had positive earnings in the past year.
In the past year AXGN had a positive cash flow from operations.
AXGN had negative earnings in each of the past 5 years.
AXGN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
AXGN's Return On Assets of -4.89% is fine compared to the rest of the industry. AXGN outperforms 64.74% of its industry peers.
With a decent Return On Equity value of -9.59%, AXGN is doing good in the industry, outperforming 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.89% | ||
| ROE | -9.59% | ||
| ROIC | N/A |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AXGN has a better Gross Margin (75.79%) than 88.42% of its industry peers.
AXGN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AXGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
2. Health
2.1 Basic Checks
AXGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AXGN has more shares outstanding
AXGN has more shares outstanding than it did 5 years ago.
AXGN has a better debt/assets ratio than last year.
2.2 Solvency
AXGN has an Altman-Z score of 3.83. This indicates that AXGN is financially healthy and has little risk of bankruptcy at the moment.
AXGN's Altman-Z score of 3.83 is fine compared to the rest of the industry. AXGN outperforms 74.74% of its industry peers.
AXGN has a debt to FCF ratio of 4318.64. This is a negative value and a sign of low solvency as AXGN would need 4318.64 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4318.64, AXGN is doing good in the industry, outperforming 66.84% of the companies in the same industry.
AXGN has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
AXGN's Debt to Equity ratio of 0.46 is in line compared to the rest of the industry. AXGN outperforms 42.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 4318.64 | ||
| Altman-Z | 3.83 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
AXGN has a Current Ratio of 3.24. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
AXGN has a Current ratio of 3.24. This is comparable to the rest of the industry: AXGN outperforms 56.84% of its industry peers.
AXGN has a Quick Ratio of 2.16. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.16, AXGN is in line with its industry, outperforming 51.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.24 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
AXGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 172.22%, which is quite impressive.
AXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.81%.
The Revenue has been growing by 11.92% on average over the past years. This is quite good.
EPS 1Y (TTM)172.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216.67%
Revenue 1Y (TTM)17.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%15.1%
3.2 Future
The Earnings Per Share is expected to grow by 46.50% on average over the next years. This is a very strong growth
AXGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.19% yearly.
EPS Next Y119.69%
EPS Next 2Y98.73%
EPS Next 3Y77.82%
EPS Next 5Y46.5%
Revenue Next Year16.31%
Revenue Next 2Y16.3%
Revenue Next 3Y16.79%
Revenue Next 5Y16.19%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AXGN is valuated quite expensively with a Price/Earnings ratio of 131.77.
Based on the Price/Earnings ratio, AXGN is valued a bit cheaper than the industry average as 64.74% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of AXGN to the average of the S&P500 Index (28.22), we can say AXGN is valued expensively.
Based on the Price/Forward Earnings ratio of 59.98, the valuation of AXGN can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AXGN indicates a somewhat cheap valuation: AXGN is cheaper than 68.95% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.86. AXGN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 131.77 | ||
| Fwd PE | 59.98 |
4.2 Price Multiples
AXGN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AXGN is cheaper than 63.16% of the companies in the same industry.
66.84% of the companies in the same industry are more expensive than AXGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69049.47 | ||
| EV/EBITDA | 168.71 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AXGN's earnings are expected to grow with 77.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)N/A
EPS Next 2Y98.73%
EPS Next 3Y77.82%
5. Dividend
5.1 Amount
AXGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.13
+0.65 (+3.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners82.17%
Inst Owner Change1.34%
Ins Owners1.68%
Ins Owner Change0.06%
Market Cap759.54M
Analysts84.29
Price Target26.65 (55.58%)
Short Float %4.62%
Short Ratio3.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)619.98%
Min EPS beat(2)114.46%
Max EPS beat(2)1125.49%
EPS beat(4)4
Avg EPS beat(4)367.4%
Min EPS beat(4)13.49%
Max EPS beat(4)1125.49%
EPS beat(8)8
Avg EPS beat(8)216.76%
EPS beat(12)11
Avg EPS beat(12)160.97%
EPS beat(16)15
Avg EPS beat(16)130.59%
Revenue beat(2)1
Avg Revenue beat(2)0.52%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)1.33%
Revenue beat(4)2
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-3.33%
Max Revenue beat(4)8.25%
Revenue beat(8)5
Avg Revenue beat(8)0.55%
Revenue beat(12)6
Avg Revenue beat(12)0.08%
Revenue beat(16)8
Avg Revenue beat(16)-0.07%
PT rev (1m)0%
PT rev (3m)38.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.58%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 131.77 | ||
| Fwd PE | 59.98 | ||
| P/S | 4.05 | ||
| P/FCF | 69049.47 | ||
| P/OCF | 167.48 | ||
| P/B | 7.31 | ||
| P/tB | 7.72 | ||
| EV/EBITDA | 168.71 |
EPS(TTM)0.13
EY0.76%
EPS(NY)0.29
Fwd EY1.67%
FCF(TTM)0
FCFY0%
OCF(TTM)0.1
OCFY0.6%
SpS4.23
BVpS2.34
TBVpS2.22
PEG (NY)1.1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.89% | ||
| ROE | -9.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.79% | ||
| FCFM | 0.01% |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 4318.64 | ||
| Debt/EBITDA | 10.44 | ||
| Cap/Depr | 57.73% | ||
| Cap/Sales | 2.41% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 99.67% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.24 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | 3.83 |
F-Score6
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)172.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216.67%
EPS Next Y119.69%
EPS Next 2Y98.73%
EPS Next 3Y77.82%
EPS Next 5Y46.5%
Revenue 1Y (TTM)17.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%15.1%
Revenue Next Year16.31%
Revenue Next 2Y16.3%
Revenue Next 3Y16.79%
Revenue Next 5Y16.19%
EBIT growth 1Y84.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1562.83%
EBIT Next 3Y220.78%
EBIT Next 5YN/A
FCF growth 1Y100.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.34%
OCF growth 3YN/A
OCF growth 5YN/A